IXICO: Trading Update

IXICO plc

20 October 2026

 

IXICO plc

(“IXICO”, the “Company” or the “Group”)

Trading update for year ending 30 September 2026

28% revenue growth expected - exceeding previous guidance

Cash and strategy in place for continued value trajectory

20 October 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global TechBio leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today provides a trading update for the financial year ending 30 September 2026.

• FY26 revenues expected to be £8.3 million (2025: £6.5 million), beating market expectations.  Year-on-year revenues increase by 28%.  This additional growth exceeds the upgraded revenue guidance of 7 July 2026 (which moved revenue expectations from £7.5 million to £8.0 million), after an acceleration in analysis orders during the final quarter of the year.   

• Year-end order book of £16.0 million (2025: £13.8 million) further improving revenue visibility, and prospects for future growth.

• Year-end cash of £10.4 million (2025: £3.5 million).  Year-on-year increase reflects a £9.4 million (net of fees) capital raise completed in April 2026.

• Full year loss before interest, tax, depreciation, and amortisation (“EBITDA”) is expected to improve on market expectations.  IXICO  is increasing investment for growth. However, the Group's revenue performance is expected to drive improved EBITDA versus existing guidance of a £1.7 million loss.

IXICO’s growth is driven by momentum in the neuroscience market, increasing demand for its specialist neuroimaging and biomarker analytics capabilities, and the execution of its Innovate, Lead, Scale strategy, maximising its ability to capture the market opportunity. The Group continues to secure new clinical trial programmes, expand relationships with existing customers and diversify its revenues across neurological diseases, clinical trial phases and customer types.

Bram Goorden, CEO of IXICO, said:  “This has been a year of tremendous progress for IXICO. If FY25 was a year where the Company returned to growth, FY26 saw clear acceleration of this trend thanks to disciplined execution of our strategy driving strong demand for our neuroimaging capabilities. We are winning new customers, expanding existing relationships and diversifying our business, while improving gross margins.  Looking ahead, we are particularly excited by the opportunity to unlock the commercial potential of our IXI™ platform through our TechBio strategy. Supported by our recent fundraising and partnerships, we enter FY27 with strong momentum and confidence in our ability to deliver sustainable growth and create increased long-term shareholder value."

Audited results for the year ending 30 September 2026 will be announced in December 2026.  

Ends

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact: For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech’s, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s.  Image data is interrogated by the Platform and IXICO’s expert scientists translating complex data into clinically meaningful insights while minimizing data variability and increasing reproducibility.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.